Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).

INTRODUCTION: Direct oral anticoagulants (DOACs) are emerging options for portal vein thrombosis (PVT) in cirrhosis, though their safety and efficacy remain uncertain. We evaluated the efficacy and safety of dabigatran for PVT recanalization. METHODS: Eighty-four patients with cirrhosis and PVT were prospectively randomized to receive dabigatran(n=42; 150 mg twice daily) or placebo(n=42) for 12 months. The primary endpoint was complete recanalization(CR) of the portal vein at 12 months. Secondary endpoints included safety, clinical outcomes, and changes in the liver disease severity scores and mortality. RESULTS: Patients were predominantly male(71.4%), with a mean age of 48.5± 9.1 years and median Child-Turcotte-Pugh(CTP) score of 8(7-8). Medium-to-large varices were present in 60.7%, prior variceal bleeding in 45.2%, and ascites in 54.8%. At 12 months, complete recanalization occurred in 27/42(64.3%) in dabigatran group compared to 9/42(21.4%) in the placebo group(p<0.001). On multivariable Cox regression, dabigatran treatment was independently associated with complete recanalization (adjusted HR, 4.35; 95% CI, 2.03-9.36; P<0.001), along with a more favorable baseline ALBI score (adjusted HR, 2.02; 95% CI, 1.02-4.01; P=0.044). Variceal bleeding episodes were less frequent with dabigatran (3 vs. 12; p = 0.008). Compared with placebo, patients receiving dabigatran showed greater improvement in CTP scores (ΔCTP -0.57 ± 1.17 vs. 0.19 ± 1.17; P=0.004) and ALBI scores (ΔALBI -0.29 ± 0.82 vs. 0.06 ± 0.49; P=0.020). Longitudinal mixed-effects analysis demonstrated significantly different trajectories for CTP and ALBI scores, whereas MELD trajectories were comparable between groups. CONCLUSION: In patients with Child-Pugh A/B cirrhosis and chronic PVT, dabigatran significantly increased complete portal vein recanalization compared with placebo with fewer bleeding events. The observed differences in clinical events and liver disease severity scores could be considered exploratory requiring evaluation in larger comparative studies.

Authors

Institutions

Publication Details

Journal
The American Journal of Gastroenterology
Published
2026-11-12
DOI
https://doi.org/10.14309/ajg.0000000000004254
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).

Amar Mukund, Shalini Thapar Laroia, Ankur Jindal, Shiv Kumar Sarin et al.
The American Journal of Gastroenterology
Liver Disease and Transplantation
article

Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).

Amar Mukund, Shalini Thapar Laroia, Ankur Jindal, Shiv Kumar Sarin, Srinivasa Reddy Golamari, Babu Lal Meena, Ankit Bhardwaj, Guresh Kumar, Vinod Arora, Rajan Vijayaraghavan
article en

Abstract

INTRODUCTION: Direct oral anticoagulants (DOACs) are emerging options for portal vein thrombosis (PVT) in cirrhosis, though their safety and efficacy remain uncertain. We evaluated the efficacy and safety of dabigatran for PVT recanalization. METHODS: Eighty-four patients with cirrhosis and PVT were prospectively randomized to receive dabigatran(n=42; 150 mg twice daily) or placebo(n=42) for 12 months. The primary endpoint was complete recanalization(CR) of the portal vein at 12 months. Secondary endpoints included safety, clinical outcomes, and changes in the liver disease severity scores and mortality. RESULTS: Patients were predominantly male(71.4%), with a mean age of 48.5± 9.1 years and median Child-Turcotte-Pugh(CTP) score of 8(7-8). Medium-to-large varices were present in 60.7%, prior variceal bleeding in 45.2%, and ascites in 54.8%. At 12 months, complete recanalization occurred in 27/42(64.3%) in dabigatran group compared to 9/42(21.4%) in the placebo group(p<0.001). On multivariable Cox regression, dabigatran treatment was independently associated with complete recanalization (adjusted HR, 4.35; 95% CI, 2.03-9.36; P<0.001), along with a more favorable baseline ALBI score (adjusted HR, 2.02; 95% CI, 1.02-4.01; P=0.044). Variceal bleeding episodes were less frequent with dabigatran (3 vs. 12; p = 0.008). Compared with placebo, patients receiving dabigatran showed greater improvement in CTP scores (ΔCTP -0.57 ± 1.17 vs. 0.19 ± 1.17; P=0.004) and ALBI scores (ΔALBI -0.29 ± 0.82 vs. 0.06 ± 0.49; P=0.020). Longitudinal mixed-effects analysis demonstrated significantly different trajectories for CTP and ALBI scores, whereas MELD trajectories were comparable between groups. CONCLUSION: In patients with Child-Pugh A/B cirrhosis and chronic PVT, dabigatran significantly increased complete portal vein recanalization compared with placebo with fewer bleeding events. The observed differences in clinical events and liver disease severity scores could be considered exploratory requiring evaluation in larger comparative studies.

The American Journal of Gastroenterology
Institute of Liver and Biliary Sciences (IN)
Good health and well-being
Liver Disease and Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon